QS Research · Michael Burry's Scion Capital analyst template · 2006
Trevi Therapeutics, Inc. (TRVI)
As of 2026-11-09 · 12/15 boxes filled from SEC filings and market data
Conclusion: WATCH
Conviction low · base case none · downside -84% · upside 0%
The market is not missing the pipeline; it is already capitalizing it. Trevi has no product revenue, no approved product and TTM to Jun 30, 2026 EBIT of -$59.6M (N10) and FCF of -$52.9M (N16), while the $1.72B EV (N20) sits on only $318.9M cash/ST investments (N17). At the company's own 6.35x P/B (N22) on $321.5M book (N19), the base-case value is essentially today's $14.33 close (N1); the cash-only downside is $2.23/share, about -84.4%, and no operating forecast supports a higher multiple. Positive Phase 2 data and FDA alignment are real, but the binary readouts in 2027-2028 make a short too risky and the current price leaves no deep-value margin of safety, so this is a watch.
Key numbers
- Share price: $14.33
- Market cap: $2.04B
- Latest financial period: TTM to Jun 30, 2026
- Price / book: 6.35x
The 15 boxes
- ✓ 1. Long-form business notes
Trevi is a pre-revenue, clinical-stage biopharmaceutical company whose only asset is Haduvio (oral nalbuphine ER); the XBRL record for FY2020 through FY2025 shows no revenue and widening operating losses (operating income -$32.5M in FY2020 to -$49.3M in FY2025; operating cash flow -$29.0M to -$42.1M). The business has narrowed since FY2020: the oldest filing covered pruritus/prurigo nodularis, uremic pruritus, LID and IPF cough, while the latest 10-K (dated 2026-03-17) is solely a chronic-cough story across IPF, non-IPF ILD and RCC, with two IPF Phase 3 trials and the RCC and non-IPF ILD Phase 2b trials guided to 2026. The balance sheet at 2025-12-31 showed $18.9M cash plus $169.3M short-term investments and $183.2M total equity, against $99.6M equity a year earlier and diluted shares of 134.75M versus 101.97M. No unit economics exist yet: there are no sales, and the value rests on trial readouts and a planned in-house U.S. specialty sales force.
- ✓ 2. Competitive advantage
There is no durable competitive advantage to measure yet: Trevi has never generated product revenue, has no approved product and reports operating losses and negative operating cash flow in every year from FY2020 through FY2025, so the margin and return history is simply an absence of both. The only exclusivity the sources describe is contractual - an exclusive worldwide Keenova license to nalbuphine hydrochloride patents and know-how, subject to milestones and royalties - plus a possible first-mover position in IPF and non-IPF ILD chronic cough and U.S. RCC, where the 10-K says no therapies are approved. Competition is real and better funded: GSK's camlipixant, Merck's gefapixant (approved in Japan, the UK, Switzerland and the E.U., FDA filing withdrawn) and Nocion's taplucainium, plus unprescribed standbys such as benzonatate, opioids and corticosteroids.
- ✓ 3. 10-Q takeaways
The Q2 2026 10-Q (quarter ended June 30, 2026, filed August 6, 2026) shows a pre-revenue clinical-stage company: no product sales, Q2 2026 net loss of $17.797M vs $12.301M in Q2 2025, and loss from operations of $20.509M vs $13.722M as Phase 3 OCEAN-1 and Phase 2b LAKE ramped. The gap to net loss is interest income ($2.693M in Q2 2026), not operating profit. Cash, cash equivalents and marketable securities were $318.9M at June 30, 2026 after the April 2026 offering (net ~$162.3M), and management extends its stated runway into 2030. There is no numeric financial guidance in either the 10-Q or the same-quarter earnings release, only trial-timing milestones; the 10-Q states risk factors are unchanged materially from the FY2025 10-K except for items noted in Item 1A.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.